SELLAS Life Sciences (SLS) 10-Q2016 Q2 Quarterly report

Filed: 9 Aug 16, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. sophomore Avg

New words: adjourned, admission, AEs, albeit, assembled, asymptomatic, attain, beneficial, bid, burn, calendar, cancellation, characterize, characterized, clotting, consecutive, consent, covenant, delisted, delisting, depletion, difficulty, disorder, dispute, eventual, expended, extension, Fast, feature, floor, guaranty, inhibit, losing, microscopic, mild, modification, monthly, neoadjuvant, notification, opinion, orphan, pink, precisely, predispose, prospective, reaction, reactive, reevaluate, regain, registered, regular, removed, repurchase, reveal, reversal, satisfy, suspended, synergistic, systematic, testimony, Track, unamortized, unavailable, unblind, undergo, unreimbursed, unrestricted, wrongdoing

Removed: abbreviated, ABIC, abroad, absence, adjustment, adult, Advancement, aggressive, ANDA, Anderson, arising, arrangement, assume, assuming, axillary, bioavailability, body, candidate, center, certification, charge, Chronic, CINV, claim, clear, closely, CML, commencing, competition, complaint, complex, computed, defend, depend, developed, directly, dismissed, distribute, distribution, dividing, Eastern, emetogenic, establish, Europe, expanded, extent, face, favorably, female, foregoing, formula, Foundation, function, generic, Guarantor, hematological, Henry, HJF, immunity, implementation, indemnification, indemnified, Indirect, individually, infringement, investigator, Israel, issuable, Jackson, law, led, Leukemia, leukocyte, location, loci, lymph, main, manufacturing, MDACC, Medicare, Military, moderately, molecular, multinational, nausea, NDA, NED, NeuVaxTM, North, oncoprotein, operation, operational, opportunity, partnership, pediatric, PMF, Polycythemia, PONV, power, produce, progressive, prohibit, PV, quality, receiving, reference, refusal, region, registration, reimbursed, resectable, responsibility, RINV, signature, size, sooner, SPA, strike, substance, suffered, survivor, territory, Teva, TIRF, traditional, transmucosal, undetected, varying, Vera, vomiting, Western

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

SLS similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the accompanying Quarterly Report of Galena Biopharma, Inc., (the “Company”) on Form 10-Q for the period ended June 30, 2016 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned officers of the Company certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that to their knowledge:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the Company’s financial condition and result of operations.



/s/ Mark W. Schwartz		/s/ John T. Burns
Mark W. Schwartz		John T. Burns
President and Chief Executive Officer		Vice President, Finance and Corporate Controller (Principal Accounting Officer)

August 9, 2016		August 9, 2016